| アブストラクト | BACKGROUND AND OBJECTIVES: The increasing complexity of interstitial lung disease (ILD) related to cancer-targeted monoclonal antibodies (mAbs) has emerged as a significant clinical concern. Thus, this study aimed to investigate reporting signals of four ILD subtypes detected with cancer-targeted mAbs. METHODS: This global pharmacovigilance study conducted disproportionality analyses to detect signals of ILD subtypes reported with cancer-targeted mAbs. ILD subtypes were classified into eight categories according to previous studies, of which four with a low number of reports were excluded. Five cancer-targeted monoclonal antibodies (VEGF/VEGFR, CD20, PD-1/PD-L1, HER2, and EGFR inhibitors) were included according to ATC code (L01F). Reporting signals were evaluated using reporting odds ratio (ROR) with 95% CI and information component (IC) with IC(025). RESULTS: Interstitial pneumonitis and pulmonary fibrosis showed significant disproportionate reporting signals across all drugs. Notably, interstitial pneumonitis showed significant signals with EGFR inhibitors (ROR, 47.46 [95% CI, 44.67-50.42]; IC, 5.47 [IC(0.25), 5.37]) and PD-1/PD-L1 inhibitors (45.20 [43.49-46.97]; 5.36 [5.30]), while pulmonary fibrosis showed higher signals with CD20 inhibitors (12.71 [11.30-14.31]; 3.61 [3.42]). Organising pneumonia exhibited significant signals with PD-1/PD-L1 inhibitors (ROR, 44.48 [95% CI, 39.05-50.67]; IC, 5.26 [IC(0.25), 5.04]), followed by CD20 (17.45 [13.88-21.94]; 3.95 [3.57]), and HER2 (15.95 [11.88-21.40]; 3.76 [3.26]), with the strongest signal observed with PD-1/PD-L1 inhibitors. Eosinophilic pneumonia showed significant signals with all drugs except CD20 inhibitors. CONCLUSIONS: Although causal inference cannot be drawn, this global disproportionality study highlights reporting signals between cancer-targeted mAbs and ILD subtypes, underscoring the importance of strengthening adverse event reporting systems before and after mAb administration. |
|---|
| ジャーナル名 | Respirology (Carlton, Vic.) |
|---|
| Pubmed追加日 | 2025/10/22 |
|---|
| 投稿者 | Jeong, Jinyoung; Kim, Hyunjee; Lee, Sooji; Hwang, Jiyoung; Smith, Lee; Woo, Ho Geol; Cho, Jaehyeong; Yon, Dong Keon |
|---|
| 組織名 | Department of Medicine, Kyung Hee University College of Medicine, Seoul, South;Korea.;Center for Digital Health, Medical Science Research Institute, Kyung Hee;University Medical Center, Kyung Hee University College of Medicine, Seoul, South;Department of Precision Medicine, Kyung Hee University College of Medicine,;Seoul, South Korea.;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.;Centre for Health, Performance and Wellbeing, Anglia Ruskin University,;Cambridge, UK.;Department of Public Health, Faculty of Medicine, Biruni University, Istanbul,;Turkey.;Department of Neurology, Kyung Hee University Medical Center, Kyung Hee;University College of Medicine, Seoul, South Korea.;Department of Medicine, CHA University School of Medicine, Seongnam, South Korea.;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41121456/ |
|---|
